Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

3 de junio de 2013 actualizado por: National Cancer Institute (NCI)

A Phase II Trial of R115777, a Farnesyl Transferase Inhibitor, in Combination With Gemcitabine and Cisplatin in Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase II trial to study the effectiveness of combining tipifarnib with gemcitabine and cisplatin in treating patients who have stage III or stage IV non-small cell lung cancer. Drugs used in chemotherapy such as gemcitabine and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining tipifarnib with combination chemotherapy may kill more tumor cells.

Descripción general del estudio

Descripción detallada

PRIMARY OBJECTIVES:

I. To describe the response rate in non-small cell lung cancer (NSCLC) patients receiving combination therapy with R115777, gemcitabine, and cisplatin.

SECONDARY OBJECTIVES:

I. To estimate the time to event efficacy variables including: time to progressive disease, time to treatment failure, time to death of any cause.

II. To estimate the duration of response for responding patients. III. To characterize the toxicities of R115777, gemcitabine, and cisplatin in this patient population.

TERTIARY OBJECTIVES:

I. To evaluate the association between polymorphism expression in candidate genes and clinical endpoints and toxicity to R115777, gemcitabine, and cisplatin.

OUTLINE: This is a multicenter study.

Patients receive oral tipifarnib twice daily on days 1-14, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients with at least stable disease may continue to receive oral tipifarnib alone twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 6 months for 2 years.

Tipo de estudio

Intervencionista

Inscripción (Actual)

48

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Histologically confirmed NSCLC with one of the following classifications:

    • Stage IIIB with pleural effusion
    • Stage IIIB and not a candidate for combined modality treatment with radiation therapy and chemotherapy
    • Stage IV
  • Measurable disease, defined as at least one lesion whose longest diameter can be accurately measured as >= 2.0 cm
  • Absolute neutrophil count (ANC) >= 1500/mm^3
  • PLT >= 100,000
  • Hgb > 10.0 g/dL
  • Direct bilirubin =< 1.5 x UNL
  • Alkaline phosphatase =< 5 x UNL
  • AST =< 3 x UNL
  • Creatinine =< 1.5 x UNL
  • ECOG Performance Status (PS) 0 or 1
  • Capable of understanding the investigational nature, potential risks and benefits of the study and able to provide valid informed consent

Exclusion Criteria:

  • Any of the following as this regimen may be harmful to a developing fetus or nursing child:

    • Pregnant women
    • Breastfeeding women
    • Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], surgical sterilization, subcutaneous implants, or abstinence, etc.)
  • Any of the following prior therapies:

    • Prior chemotherapy for NSCLC (exception: therapies used as a radiosensitizer such as low-dose weekly cisplatin and carbo/taxol with XRT)
    • Prior radiation > 25% of bone marrow
    • Prior immunotherapy, biologic or gene therapy
  • New York Heart Association classification III or IV
  • CNS metastases
  • Uncontrolled infection
  • Any other severe, underlying diseases that are, in the judgment of the investigator, inappropriate for entry into this study
  • Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinomas, or other cancer from which the patient has been disease-free for at least five years
  • Pre-existing peripheral neuropathy (motor or sensory) > grade 1 per NCI Common Toxicity Criteria (CTC)
  • Known peripheral vascular disease or a history of deep vein thrombosis

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Treatment (tipifarnib, gemcitabine, cisplatin)

Patients receive oral tipifarnib twice daily on days 1-14, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients with at least stable disease may continue to receive oral tipifarnib alone twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Estudios correlativos
Administrado oralmente
Otros nombres:
  • R115777
  • Zarnestra
Dado IV
Otros nombres:
  • Gemzar
  • gemcitabina
  • dfdc
  • clorhidrato de difluorodesoxicitidina
Dado IV
Otros nombres:
  • CDDP
  • DDP
  • CACP
  • CPDD

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of confirmed tumor responses, defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart
Periodo de tiempo: Up to 18 weeks (6 courses)
Ninety-five percent confidence intervals for the true success proportion will be calculated.
Up to 18 weeks (6 courses)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Survival time
Periodo de tiempo: Time from registration to death due to any cause, assessed up to 2 years
The distribution of survival time will be estimated using the method of Kaplan-Meier.
Time from registration to death due to any cause, assessed up to 2 years
Time to disease progression
Periodo de tiempo: Time from registration to documentation of disease progression, assessed up to 2 years
The distribution of time to progression will be estimated using the method of Kaplan-Meier.
Time from registration to documentation of disease progression, assessed up to 2 years
Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented
Periodo de tiempo: Up to 2 years
Up to 2 years
Time to treatment failure
Periodo de tiempo: Time from the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, or refusal, assessed up to 2 years
Time from the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, or refusal, assessed up to 2 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Alex Adjei, Mayo Clinic

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de octubre de 2003

Finalización primaria (Actual)

1 de abril de 2004

Fechas de registro del estudio

Enviado por primera vez

6 de marzo de 2003

Primero enviado que cumplió con los criterios de control de calidad

6 de marzo de 2003

Publicado por primera vez (Estimar)

7 de marzo de 2003

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

4 de junio de 2013

Última actualización enviada que cumplió con los criterios de control de calidad

3 de junio de 2013

Última verificación

1 de junio de 2013

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir